Radiotherapy: The importance of local control in pancreatic cancer

Nature Reviews Clinical Oncology

Volumn 9, Issue 1, 2012, Pages 9-10

  Ben Josef, Edgar ^a   Lawrence, Theodore S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; SMAD4 PROTEIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; DOSIMETRY; DRUG CYTOTOXICITY; EVIDENCE BASED MEDICINE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; LOCAL THERAPY; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT SAFETY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RADIATION INJURY; RADIOSENSITIVITY; SHORT SURVEY; SYSTEMIC THERAPY; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; SMAD4 PROTEIN;

EID: 84655166493     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.182     Document Type: Short Survey

References (10)

1. Loehrer, P. J. Sr et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 29, 4105-4112 (2011).
2. Iacobuzio-Donahue, C. A. et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J. Clin. Oncol. 27, 1806-1813 (2009).
3. Chauffert, B. et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann. Oncol. 19, 1592-1599 (2008).
4. Ceha, H. M. et al. Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma. Cancer 89, 2222-2229 (2000).
5. Shewach, D. S. & Lawrence, T. S. Antimetabolite radiosensitizers. J. Clin. Oncol. 25, 4043-4050 (2007). (Pubitemid 47492948)
6. Lawrence T. S., Chang, E. Y., Hahn, T. M., Hertel, L. W. & Shewach, D. S. Radiosensitization of pancreatic cancer cells by 2', 2'-difluoro-2'- deoxycytidine. Int. J. Radiat. Oncol. Biol. Phys. 34, 867-872 (1996).
7. McGinn, C. J. et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 19, 4202-4208 (2001). (Pubitemid 33081637)
8. Bockbrader, M. & Kim, E. Role of intensity-modulated radiation therapy in gastrointestinal cancer. Expert. Rev. Anticancer Ther. 9, 637-647 (2009).
9. Ben-Josef, E. et al. Phase I/II radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G.) for unresectable pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 81 (Suppl. 2), 127-128 (2011).
10. Murphy, J. D. et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 68, 801-808 (2007). (Pubitemid 46818734)